Immunocore vs Krystal Biotech
IMCR and KRYS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMCR and KRYS compare
Krystal Biotech is the larger company, worth 6.3 times as much as Immunocore ($9.8B against $1.6B).
Krystal Biotech grew revenue faster over the last twelve months (22.6% versus 21.0% for Immunocore).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with −4.2% at Immunocore.
Krystal Biotech scores higher on the StockData Score (10 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMCR | KRYS |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $9.8B |
| Share price | $30.49 | $332.29 |
| Change, 1 year | −7.2% | 79.6% |
| Change, 5 years | −20.0% | 548% |
| Beta (5Y) | 0.70 | 0.84 |
| Employees | 524 | 295 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 3 | 3 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 41.6× |
| P/S | 3.6× (better) | 22.3× |
| P/B | 3.7× (better) | 7.2× |
| EV/EBITDA | – | 45.5× |
| P/FCF | – | 38.2× |
| FCF yield | −2.6% | 2.6% (better) |
| Fair value | $33.14 | $157.63 |
| Margin of safety | 8.0% (better) | −111% |
| Growth | ||
| Revenue growth (TTM) | 21.0% | 22.6% (better) |
| Net income growth (TTM) | – | 64.6% |
| EPS growth (TTM) | – | 62.2% |
| Profitability | ||
| Gross margin | 98.9% | – |
| Operating margin | −5.2% | 44.9% (better) |
| Net margin | −4.2% | 54.8% (better) |
| FCF margin | −9.6% | 58.5% (better) |
| Return on equity | −4.5% | 20.1% (better) |
| Return on invested capital | – | 45.3% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1.8× | – |
| Current ratio | 4.47 | 8.32 (better) |
| Altman Z-score | 1.52 | 43.30 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 102% |
| Held by insiders | 15.5% | 17.2% |
| Insider net buying, 12 months | −$5.6M (better) | −$105M |
| Short interest, % of float | – | 14.2% |
Go deeper
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.